A retrospective review of 539 consecutive hospitalized patients with viral pneumonia indicates that continuing in-hospital use of ACEI or ARB may reduce the risk of pneumonia and death (ACEI, odds ratio, 0.64 for risk of pneumonia; odds ratio, 0.25 for in-hospital death; ARB, odds ratio, 0.48 for risk of pneumonia; odds ratio, 0.75 for in-hospital death).30 A more recent study by Liu et al shows that plasma Ang II concentration is significantly elevated after SARS-COV-2 infection.31 The influence of ACEI/ARB on COVID-19 related outcomes has not been fully investigated. Here, AGT is linked to COVID-19.